BSEAGM/EGM2d ago · 23 Sept 2026, 04:08 pm

Revised Proceedings of the 21st Annual General Meeting (AGM) of the Company

Suraksha Diagnostic Ltd · 544293

✦ AI SummaryResults

Suraksha Diagnostic Ltd has held its 21st Annual General Meeting (AGM) through video conferencing, where all resolutions were passed by the requisite majority. The company declared a final dividend of ₹ 0.50 per equity share and appointed a new director. The meeting was conducted in accordance with SEBI and MCA guidelines.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment6/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Suraksha Diagnostic Ltd - 544293 - Shareholder Meeting / Postal Ballot-Outcome of AGM

Attachments (1)

📄

0e190ff7-c38b-4100-9b6a-fd3f3b240e04.pdf

pdf

Download →
View document text
Date: 23rd September, 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear Sir / Ma’am, Sub: Revised Proceedings of the 21st Annual General Meeting (AGM) of the Company Pursuant to Regulation 30 read with Part A of Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), we enclose herewith the summary of the proceedings of the 21st AGM of the Company for the FY 2025-26 held today, i.e. Tuesday, 22nd September, 2026 at 11:30 A.M. (IST) through video conferencing/other audio-visual means (VC / OAVM). We would like to advise that all the Resolutions placed for consideration at the said AGM have been passed by the Members by requisite majority. Further, the recording of the meeting will be made available on the Company’s website at: www.surakshanet.com. The voting results, in the prescribed format in terms of Regulation 44(3) of the SEBI Listing Regulations will be submitted subsequently within the prescribed time. Kindly take this on record. Thank you. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Encl: As above Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 SUMMARY OF THE PROCEEDINGS OF THE 21ST ANNUAL GENERAL MEETING (AGM) The 21st Annual General Meeting of the members of the Company was held on Tuesday, 22nd September, 2026 through video conferencing/other audio-visual means (VC/OAVM) in accordance with the various circulars issued by the Ministry of Corporate Affairs (‘MCA’) and the Securities and Exchange Board of India (‘SEBI’) and in compliance with the relevant provisions of the Companies Act, 2013 (“Act”) and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 11:30 A.M. (IST) and concluded at 12:35 P.M. (IST) (including the time allowed for e-voting). At the outset, Dr. Somnath Chatterjee, the Chairman of the Company, presided over the meeting and welcomed the Members to the 21st Annual General Meeting of the Company. Upon confirming the presence of the requisite quorum, the Meeting was declared as duly convened. The Chairman, thereafter, handed over the proceedings of the meeting to Mr. Dinesh Gupta, Chief Financial Officer (CFO) of the Company. All the Directors (except Mr. Satish Kumar Verma who could not attend the meeting due to personal reasons) attended the meeting from their respective locations. The CFO acknowledged their presence and introduced the Directors and Key Managerial Personnel (KMPs) to the Members. The CFO acknowledged the presence of the representatives of the Secretarial Auditors and Statutory Auditor of the Company. Further, Ms. Sandhya Malhotra, Practicing Company Secretary and Partner at M/s Manish Ghia and Associates, attended the meeting as Scrutinizer, overseeing the remote e- voting and e-voting at the Meeting in a fair and transparent manner. Thereafter, Ms. Ritu Mittal, CEO of the Company, briefed about the affairs of the Company and the CFO highlighted the financial performance and growth of the Company during the Financial Year 2025-26. With the consent of the Members, the Notice convening the AGM, the Auditors’ Report, and the Secretarial Audit Report for the financial year ended 31st March, 2026 were taken as read. Members were apprised that the Statutory Registers and other relevant documents, as required under the Act, along with the certificate from the Secretarial Auditor in accordance with Regulation 13 of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, were accessible in electronic mode throughout the meeting. Since there was no physical meeting of Members, the requirement for appointing proxies was not applicable for this meeting. Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 Thereafter, the Members proceeded to consider the following items of business as set out in the AGM Notice dated 12th August, 2026: Item Description of the Resolution Type of the No. Resolution ORDINARY BUSINESS 1. To receive, consider and adopt the audited standalone financial Ordinary statements of the Company for the financial year ended 31st March, 2026, together with the Reports of the Board of Directors and Auditors thereon. 2. To receive, consider and adopt the audited consolidated financial Ordinary statements of the Company for the financial year ended 31st March, 2026 together with the Report of the Auditors’ thereon. 3. To declare a final dividend of ₹ 0.50 (Fifty Paise only) per equity share of Ordinary Rs. 2/- each, being 25% for the financial year ended 31st March, 2026. 4. To appoint a Director in place of Mr. Satish Kumar Verma Ordinary (DIN: 00225444), Non-Executive Non-Independent Director, who retires by rotation and being eligible, offers himself for re-appointment. SPECIAL BUSINESS 5. Ratification of remuneration payable to M/s. S. Chhaparia & Associates, Ordinary Cost Auditor for the financial year ending 31st March, 2027. Following the tabling of the aforementioned items of business, the registered speaker shareholders were invited to raise queries or offer suggestions pertaining to any of the resolutions outlined in the Notice. Thereafter, Ms. Ritu Mittal appropriately responded to the queries raised / clarifications sought by the Members who spoke at the Meeting. Chairman informed the members that NSDL e-Voting platform would remain open for 15 minutes for the members who had not casted their votes through remote e-voting. The Chairman also advised that the Voting results, along with the scrutinizer’s report would be submitted to the BSE Limited and The National Stock Exchange of India Limited, and would also be made available on the Company’s website at www.surakshanet.com and on the NSDL’s website at www.evoting.nsdl.com. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750